Total Payments
$2,776
2024 Payments
$268.09
Companies
9
Transactions
22
Medicare Patients
1,278
Medicare Billing
$161,546
Payment Breakdown by Category
Research$1,490 (53.7%)
Other$982.12 (35.4%)
Food & Beverage$267.65 (9.6%)
Education$36.56 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,490 | 6 | 53.7% |
| Long term medical supply or device loan | $732.12 | 8 | 26.4% |
| Food and Beverage | $267.65 | 4 | 9.6% |
| Grant | $250.00 | 1 | 9.0% |
| Education | $36.56 | 3 | 1.3% |
Payments by Type
Research
$1,490
6 transactions
General
$1,286
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Radius Health, Inc. | $1,490 | 6 | $0 (2021) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $732.12 | 8 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $250.00 | 1 | $0 (2024) |
| Seattle Genetics, Inc. | $104.15 | 1 | $0 (2019) |
| GlaxoSmithKline, LLC. | $87.15 | 1 | $0 (2022) |
| TESARO, Inc. | $76.35 | 2 | $0 (2019) |
| Merck Sharp & Dohme LLC | $18.09 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $268.09 | 2 | AstraZeneca Pharmaceuticals LP ($250.00) |
| 2023 | $166.66 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($166.66) |
| 2022 | $453.21 | 5 | Novartis Pharmaceuticals Corporation ($366.06) |
| 2021 | $1,701 | 9 | Radius Health, Inc. ($1,490) |
| 2019 | $180.50 | 3 | Seattle Genetics, Inc. ($104.15) |
| 2017 | $6.55 | 1 | PFIZER INC. ($6.55) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 01/29/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $250.00 | General |
| 02/15/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 01/14/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| 12/15/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 05/05/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $87.15 | General |
| Category: IMMUNOLOGY | ||||||
| 12/22/2021 | Radius Health, Inc. | — | — | In-kind items and services | $648.97 | Research |
| Study: NEJM EMERALD manuscript | ||||||
| 12/22/2021 | Radius Health, Inc. | — | — | In-kind items and services | $368.15 | Research |
| Study: SABCS EMERALD presentation | ||||||
| 12/22/2021 | Radius Health, Inc. | — | — | In-kind items and services | $133.23 | Research |
| Study: SABCS EMERALD abstract | ||||||
| 12/16/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2021 | Radius Health, Inc. | — | — | In-kind items and services | $209.66 | Research |
| Study: NEJM EMERALD manuscript | ||||||
| 10/25/2021 | Radius Health, Inc. | — | — | In-kind items and services | $96.67 | Research |
| Study: SABCS EMERALD presentation | ||||||
| 10/25/2021 | Radius Health, Inc. | — | — | In-kind items and services | $33.45 | Research |
| Study: SABCS EMERALD abstract | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 01/15/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $54.83 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: ONCOLOGY | ||||||
| 05/29/2019 | Seattle Genetics, Inc. | — | Food and Beverage | In-kind items and services | $104.15 | General |
| 01/31/2017 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $6.55 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NEJM EMERALD manuscript | Radius Health, Inc. | $858.63 | 2 |
| SABCS EMERALD presentation | Radius Health, Inc. | $464.82 | 2 |
| SABCS EMERALD abstract | Radius Health, Inc. | $166.68 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 315 | 519 | $172,812 | $39,729 |
| 2022 | 6 | 319 | 552 | $174,492 | $42,876 |
| 2021 | 8 | 328 | 609 | $179,919 | $46,260 |
| 2020 | 7 | 316 | 547 | $146,366 | $32,680 |
Total Patients
1,278
Total Services
2,227
Medicare Billing
$161,546
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 136 | 247 | $81,141 | $16,874 | 20.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 65 | $29,687 | $7,135 | 24.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $23,160 | $5,527 | 23.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 81 | $16,443 | $5,094 | 31.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 56 | $12,955 | $2,570 | 19.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $6,966 | $1,757 | 25.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $2,460 | $771.00 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 158 | 293 | $87,721 | $20,456 | 23.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 82 | $33,046 | $9,280 | 28.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 41 | 41 | $23,577 | $5,834 | 24.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 56 | $11,326 | $2,982 | 26.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 64 | 67 | $13,797 | $2,927 | 21.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $5,025 | $1,397 | 27.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 150 | 325 | $91,935 | $22,389 | 24.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 39 | 95 | $36,380 | $11,180 | 30.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 27 | 27 | $14,574 | $3,620 | 24.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 17 | 61 | $12,085 | $3,507 | 29.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 60 | 65 | $12,831 | $2,557 | 19.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 12 | $4,542 | $1,305 | 28.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $5,178 | $1,009 | 19.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 12 | 12 | $2,394 | $693.24 | 29.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 110 | 198 | $52,804 | $11,349 | 21.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 74 | 141 | $37,326 | $7,679 | 20.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 20 | 80 | $15,456 | $4,758 | 30.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 20 | $7,170 | $1,821 | 25.4% |
About Dr. Patrick Dillon, MD
Dr. Patrick Dillon, MD is a Hematology & Oncology healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1952502718.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Dillon, MD has received a total of $2,776 in payments from pharmaceutical and medical device companies, with $268.09 received in 2024. These payments were reported across 22 transactions from 9 companies. The most common payment nature is "" ($1,490).
As a Medicare-enrolled provider, Dillon has provided services to 1,278 Medicare beneficiaries, totaling 2,227 services with total Medicare billing of $161,546. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Charlottesville, VA
- Active Since 05/30/2007
- Last Updated 08/09/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1952502718
Products in Payments
- KISQALI (Drug) $565.46
- NUCALA (Biological) $87.15
- ZEJULA (Drug) $76.35
- KEYTRUDA (Biological) $18.09
- IBRANCE (Drug) $6.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charlottesville
Michael Williams, M.d, M.D
Hematology & Oncology — Payments: $83,082
Hematology & Oncology $83,082
Craig Portell, M.d, M.D
Hematology & Oncology — Payments: $57,149
Hematology & Oncology $57,149
Kelly Davidson, M.d, M.D
Hematology & Oncology — Payments: $22,062
Hematology & Oncology $22,062
Krista Isaac, D.o, D.O
Hematology & Oncology — Payments: $9,826
Hematology & Oncology $9,826
Thomas Loughran, M.d, M.D
Hematology & Oncology — Payments: $2,149
Hematology & Oncology $2,149
Louise Man, M.d, M.D
Hematology & Oncology — Payments: $1,013
Hematology & Oncology $1,013